Data indicate that self-renewing pools of SPEAR T-cells can produce a continuous supply of effector cells capable of mediating sustained antitumor effects
PHILADELPHIA and OXFORD, United Kingdom, June 11, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that data from the pilot study of NY-ESO SPEAR T‑cells in synovial sarcoma will be published in Cancer Discovery (an American Association of Cancer Research [AACR] publication). Beyond the clinical data, some of which having been reported previously (most recently at CTOS 2017 [https://bit.ly/2mtk13W]), this peer-reviewed paper provides new insights into SPEAR T-cells and the responses they mediate in patients.
GlaxoSmithKline plc (LSE:GSK) (NYSE:GSK) exercised its option to exclusively license the right to research, develop, and commercialize NY‑ESO SPEAR T-cell therapy program in September 2017. Transition of this program to GSK is ongoing.
“Metastatic synovial sarcoma is virtually incurable with standard therapy. NY-ESO SPEAR T‑cells can mediate durable antitumor responses in these patients,” said Rafael Amado, Adaptimmune’s Chief Medical Officer. “Data published in Cancer Discovery highlight that our persisting SPEAR T-cells comprise a robust, self-regenerating pool of polyfunctional, non-exhausted T-cells capable of antitumor effects despite prolonged exposure to antigen. Our efforts to better understand the characteristics of our SPEAR T-cells post-infusion will continue as we strive to bring the most effective therapies to patients.”
"The results of the study are encouraging," said Dr Sandra D'Angelo, medical oncologist at Memorial Sloan Kettering Cancer Center. "Through this research and these results we are understanding how to better treat synovial sarcoma."
Data from Cohort 1 of the synovial sarcoma pilot study, based on twelve patients treated, included in the peer reviewed paper (data cut off 30 March 2017), is summarized below.
Compelling response data
Encouraging survival data
Characteristics of antitumor responses indicate effects are immune-mediated
Acceptable safety profile
SPEAR T-cells expand significantly in responding patients with long-term persistence and functionality
Responses in a second solid tumor, myxoid/round cell liposarcoma (MRCLS) with NY-ESO SPEAR T-cells were recently reported, and these data were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting on June 2, 2018.
Adaptimmune is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapy products. The Company’s unique SPEAR (Specific Peptide Enhanced Affinity Receptor) T‑cell platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. Adaptimmune is currently conducting clinical trials with SPEAR T-cells targeting MAGE-A4, -A10, and AFP across several solid tumor indications. GlaxoSmithKline plc (LSE:GSK) (NYSE:GSK) exercised its option to exclusively license the right to research, develop, and commercialize Adaptimmune’s NY-ESO SPEAR T-cell therapy program in September 2017. Transition of this program to GSK is ongoing. The Company is located in Philadelphia, USA and Oxfordshire, U.K. For more information, please visit http://www.adaptimmune.com
This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking statements involve certain risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those indicated by such forward-looking statements, and include, without limitation: the success, cost and timing of our product development activities and clinical trials and our ability to successfully advance our TCR therapeutic candidates through the regulatory and commercialization processes. For a further description of the risks and uncertainties that could cause our actual results to differ materially from those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our Quarterly Report filed on form 10-Q with the Securities and Exchange Commission (SEC) on May 9, 2018 and our other SEC filings. The forward-looking statements contained in this press release speak only as of the date the statements were made and we do not undertake any obligation to update such forward‑looking statements to reflect subsequent events or circumstances.
Sébastien Desprez – VP, Communications and Investor Relations
T: +44 1235 430 583
M: +44 7718 453 176
Juli P. Miller, Ph.D. – Director, Investor Relations
T: +1 215 825 9310
M: +1 215 460 8920